Vivimed Labs (NSE:VIVIMEDLAB) Research & Development: ₹0.0 Mil (TTM As of Dec. 2025)


NSE:VIVIMEDLAB Vivimed Labs Ltd NSE:VIVIMEDLAB
33 GF Score
Price ₹5.71
GF Value ₹2.57
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Vivimed Labs Research & Development?

Vivimed Labs NSE:VIVIMEDLAB -0.87% 33 Research & Development is ₹0.0 Mil as of Dec. 2025. GuruFocus rates NSE:VIVIMEDLAB with a GF Score™ of 33/100 and a GF Value™ of ₹2.57 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Vivimed Labs's Research & Development for the three months ended in Dec. 2025 was ₹0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was ₹0.0 Mil.

Vivimed Labs  (NSE:VIVIMEDLAB) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Vivimed Labs Research & Development Related Terms

Vivimed Labs Research & Development Historical Data

* Premium members only.

The historical data trend for Vivimed Labs's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivimed Labs Research & Development Chart

Vivimed Labs Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 264.37 3.37 2.66 2.11 4.22

Vivimed Labs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:VIVIMEDLAB
33GF Score
Vivimed Labs Ltd NSE:VIVIMEDLAB
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vivimed Labs Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0.0 Mil mean?
Vivimed Labs (NSE:VIVIMEDLAB) has a Research & Development of ₹0.0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Vivimed Labs and its competitors.
Is Vivimed Labs' Research & Development too high?
Vivimed Labs' current Research & Development is ₹0.0 Mil. Overall, Vivimed Labs has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vivimed Labs' Research & Development compare to ZTS?
Vivimed Labs' Research & Development of ₹0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Vivimed Labs and its competitors. Vivimed Labs's current Research & Development is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivimed Labs stock overvalued right now?
Based on GuruFocus' analysis, Vivimed Labs (NSE:VIVIMEDLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2.57, compared to a current price of ₹5.71 — trading 122.2% above its estimated fair value. The current Research & Development is ₹0.0 Mil. Vivimed Labs' overall GF Score™ is 33/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Vivimed Labs (NSE:VIVIMEDLAB), the current Research & Development is ₹0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vivimed Labs (NSE:VIVIMEDLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Vivimed Labs stock appears to be overvalued. The current stock price of ₹5.71 is trading 122.2% above its estimated GF Value™ of ₹2.57. GuruFocus considers Vivimed Labs to be Significantly Overvalued.

Key valuation signals for NSE:VIVIMEDLAB:

  • Research & Development: ₹0.0 Mil
  • GF Value™: ₹2.57 vs. price of ₹5.71 (122.2% above fair value)
  • GF Score™: 33/100 with 7 warning signs

No single metric tells the full story. See the NSE:VIVIMEDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vivimed Labs Business Description

Other Exchanges 532660:India
Address Green Lands, Beside The Plaza Hotel, D.No. 6-3-866/1/G1, 3rd & 4th Floor, GMR Towers, Begumpet, Hyderabad, TG, IND, 500016
Vivimed Labs Ltd is an India-based company that is engaged in the Business of Active pharmaceutical ingredients, Intermediates, Nutraceutical ingredients, CDMO Finished Dosage Formulation, Specialty Chemicals, and Retail Branded Formulation manufacturing. The company has three reportable segments: the Speciality Chemicals Business, the Pharma Business, and others. The majority of revenue is earned through the Pharma business.
33GF Score

Get the complete analysis for NSE:VIVIMEDLAB

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹5.71
Price
₹2.57
GF Value